Search Results - "Clemons, Mark J."
-
1
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
Published in Journal of clinical oncology (20-06-2017)“…Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer…”
Get full text
Journal Article -
2
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update
Published in Journal of clinical oncology (10-12-2017)“…Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the…”
Get full text
Journal Article -
3
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review
Published in Supportive care in cancer (01-02-2021)“…Purpose Bone-modifying agents (BMAs) for bone metastases are commonly prescribed for many years even though randomized clinical trials are only 1–2 years in…”
Get full text
Journal Article -
4
Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer
Published in Anticancer research (01-05-2009)“…Background: Changes in the receptor profile between primary and metastatic breast cancer tissue have been suggested. The degree of hormone receptor discordance…”
Get full text
Journal Article -
5
Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy
Published in Journal of clinical oncology (20-10-2006)“…This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in…”
Get full text
Journal Article -
6
Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines
Published in Journal of clinical oncology (10-12-2009)“…Anthracyclines are a component of breast cancer chemotherapy regimens in both adjuvant and metastatic settings. Anthracycline rechallenge for metastatic…”
Get full text
Journal Article -
7
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Published in Journal of clinical oncology (01-03-2022)“…To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in…”
Get full text
Journal Article -
8
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Published in European journal of cancer (1990) (01-02-2023)“…The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast…”
Get full text
Journal Article -
9
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27
Published in JNCI : Journal of the National Cancer Institute (01-09-2018)“…Celecoxib and low-dose aspirin might decrease risk of breast cancer recurrence. In the Canadian Cancer Trials Group MA.27, postmenopausal hormone…”
Get full text
Journal Article -
10
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
Published in Clinical breast cancer (01-06-2008)“…Abstract In this phase III, multinational, randomized trial, the International Breast Cancer Study Group, Breast International Group, and the National Surgical…”
Get full text
Journal Article -
11
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
Published in Breast cancer research and treatment (01-07-2014)“…Biomarkers of bone turnover, including urine N -telopeptide (uNTx), have been used as surrogate measures of response to bone-targeted therapies. Vascular…”
Get full text
Journal Article -
12
Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines
Published in The oncologist (Dayton, Ohio) (01-11-2013)“…Learning Objectives Summarize findings regarding the media's portrayal of bevacizumab with each phase of therapeutic development. Identify media sources of…”
Get full text
Journal Article -
13
Lost in Transition? Thoughts on Retirement—“Will You Still Need Me, Will You Still Feed Me, When I'm Sixty‐Four?”
Published in The oncologist (Dayton, Ohio) (2013)“…Oncologists should plan for a future beyond full‐time oncology, but there is little practical guidance for a successful transition into retirement. This paper…”
Get full text
Journal Article -
14
Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
Published in Critical reviews in oncology/hematology (01-10-2009)“…Abstract Bone is the most common site of metastatic spread in breast cancer patients. The use of bisphosphonates (BPs) in women with bone metastases from…”
Get full text
Journal Article -
15
A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
Published in SpringerPlus (21-10-2015)“…This phase I/II neoadjuvant trial (ClinicalTrials.gov identifier NCT00066443) determined maximally-tolerated doses (MTD), dose-limiting toxicities,…”
Get full text
Journal Article -
16
Delivery of cancer care via an outpatient telephone support line: A cross-sectional study of oncology nursing perspectives on quality and challenges
Published in Journal of clinical oncology (01-10-2022)“…427 Background: Patient support lines (PSLs) help in triaging clinical problems, addressing patient queries and assist in navigating a complex…”
Get full text
Journal Article -
17
Can synthetic data accurately mimic oncology clinical trials?
Published in Journal of clinical oncology (01-06-2023)“…1554 Background: There is strong interest by researchers, the pharmaceutical industry, medical journal editors, funders of research, and regulators in sharing…”
Get full text
Journal Article -
18
Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach
Published in Journal of clinical oncology (01-06-2023)“…e24126 Background: Vasomotor symptoms (VMS), such as hot flashes, are a common reason for early discontinuation of endocrine therapy for patients (pts) with…”
Get full text
Journal Article -
19
The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials
Published in Journal of clinical oncology (20-05-2020)“…Abstract only e14099 Background: Randomized trials are considered the gold standard when assessing the efficacy of new therapeutic agents. In settings where…”
Get full text
Journal Article -
20
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
Published in Annals of oncology (01-09-2009)“…Decisions about systemic treatment of women with metastatic breast cancer are often based on estrogen receptor (ER), progesterone receptor (PgR), and Her2…”
Get full text
Journal Article